Opioid trials: time for a new approach? Enriched enrollment randomized gradual withdrawal designs

References

• 1. Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology 65(Suppl. 4), S32–S49 (2005).
  MedlineGoogle Scholar
• 2. Nadeau SE, Wu JK, Lawhern RA. Opioids and chronic pain: an analytic review of the clinical evidence. Front. Pain. Res. 2, 721357 (2021).
  Google Scholar
• 3. Cherny N, Ripamonti C, Pereira J et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J. Clin. Oncol. 19, 2542–2554 (2001).
  Medline CASGoogle Scholar
• 4. Quang-Cantagrel N, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth. Analg. 90, 933–937 (2000).
  Medline CASGoogle Scholar
• 5. Banks S, Kerns R. Explaining high rates of depression in chronic pain: a diathesis-stress framework. Psychol. Bull. 119, 95–110 (1996).
  Google Scholar
• 6. Hale ME, Ahdieh H, Ma T, Rauck R, Oxymorphone ER Study Group 1. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J. Pain 8, 175–184 (2007).
  Medline CASGoogle Scholar
• 7. Breivik H, Borchgrevink PC, Allen SM et al. Assessment of pain. Br. J. Anaesthesia 101, 17–24 (2008).
  Medline CASGoogle Scholar
• 8. Kim J, Lee KS, Kong SW et al. Correlations between electrically quantified pain degree, subjectively assessed visual analogue scale, and the McGill Pain Questionnaire: a pilot study. Ann. Rehabil. Med. 38, 665–672 (2014).
  MedlineGoogle Scholar
• 9. Moore RA, Wiffen PJ, Eccleston C et al. Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting. Pain 156, 1382–1395 (2015).
  MedlineGoogle Scholar
• 10. Meske DS, Lawal OD, Elder H, Langberg V, Paillard F, Katz N. Efficacy of opioids versus placebo in chronic pain: a systematic review and meta-analysis of enriched enrollment randomized withdrawal trials. J. Pain Res. 11, 923–934 (2018).
  Medline CASGoogle Scholar
• 11. Gimbel J, Spierings ELH, Katz N, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a Phase III, enriched enrollment, randomized withdrawal study. Pain 157(11), 2517–2526 (2016).
  Medline CASGoogle Scholar
• 12. Kawamata M, Iseki M, Kawakami M et al. Efficacy and safety of controlled-release oxycodone for the management of moderate to severe chronic low back pain in Japan: results of an enriched enrollment randomized withdrawal study followed by an open-label extension study. J. Pain Res. 12, 363–375 (2019).
  Medline CASGoogle Scholar
• 13. Shaheed CA, Maher CG, Williams KA, Day R, McLachlan AJ. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain. A systematic review and meta-analysis. JAMA Intern. Med. 176(7), 958–968 (2016).
  MedlineGoogle Scholar
• 14. Busse JW, Wang L, Kamaleldin M et al. Opioids for chronic noncancer pain. A systematic review and meta-analysis. JAMA 320, 2448–2460 (2018).
  MedlineGoogle Scholar
• 15. Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics. Focus on methodology. Clin. J. Pain 25, 797–807 (2009).
  MedlineGoogle Scholar
• 16. Kopec JA, Abrahamowicz M, Esdaile JM. Randomized discontinuation trials: utility and efficiency. J. Clin. Epidemiol. 46(9), 959–971 (1993).
  Medline CASGoogle Scholar
• 17. Kim Y. Missing data handling in chronic pain trials. J. Biopharm. Stat. 21(2), 311–325 (2011).
  Medline CASGoogle Scholar
• 18. Schneider LS, Tariot PN, Dagerman KS et al. Effective of atypical antipshychotic drugs in patients with Alzheimer’s disease. N. Engl. J. Med. 355, 1525–1538 (2006).
  Medline CASGoogle Scholar
• 19. Dehbi H, Royston P, Hackshaw A. Life expectancy differences and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. BMJ 357, j2250 (2017).
  MedlineGoogle Scholar
• 20. Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med. Res. Methodol. 13, 152 (2013).
  MedlineGoogle Scholar
• 21. Da Costa BR, Pereira TV, Saadat P et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ 375, n2321 (2021).
  MedlineGoogle Scholar
• 22. Skelly AC, Chou R, Dettori JR et al. Noninvasive nonpharmacological treatment for chronic pain: a systematic review. Comparative Effectiveness Review No. 209. AHRQ Publication No. 18-EHC013-EF doi:10.23970/AHRQEPCCER209 (2018) (Epub ahead of print).
  Google Scholar
• 23. Skelly AC, Chou R, Dettori JR et al. Noninvasive nonpharmacological treatment for chronic pain: a systematic review update. Comparative Effectiveness Review No. 227. AHRQ Publication No. 20-EHC009. doi:10.23970/AHRQEPCCER227 (2020) (Epub ahead of print).
  Google Scholar
• 24. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert ASB. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ 350, h2698 (2015).
  MedlineGoogle Scholar
• 25. Xu KY, Hartz SM, Borodovsky JT, Bierut LJ, Grucza RA. Association between benzodiazepine use with or without opioid use and all-cause mortality in the United States, 1999–2015. JAMA Network Open 3(12), e2028577 (2020).
  Google Scholar
• 26. Bohnert ASB, Valenstein M, Bair MJ et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 305, 1315–1321 (2011).
  Medline CASGoogle Scholar
• 27. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med. 5, 13–22 (2011).
  MedlineGoogle Scholar
• 28. Cowley NJ, Owen A, Bion JF. Interpreting arterial blood gas results. BMJ 346(f16), 1–7 (2013).
  Google Scholar
• 29. Krebs EE, Lorenz KA, Bair MJ et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J. Gen. Intern. Med. 24(6), 733–738 (2009).
  MedlineGoogle Scholar